IQVIA (IQV) vs Medpace (MEDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IQVIA (IQV) has outperformed Medpace (MEDP) over the past year, gaining 29.1% versus a gain of 13.5%. Over five years, MEDP leads with a +222.2% price change compared with +4.0% for IQV. IQVIA is the larger company by market cap ($42.61 billion vs $16.82 billion), about 2.5 times the size, while Medpace is growing revenue faster (+20.0% vs +5.9%).
On valuation, IQVIA trades at a lower forward P/E (17.9x vs 31.2x for Medpace). Medpace converts more of its revenue into profit, with a net margin of 17.8% versus 8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IQV | MEDP |
|---|---|---|
| Share price | $258.88 | $602.70 |
| Market cap | $42.61B | $16.82B |
| 1-day change | +0.30% | -0.26% |
| YTD return | +14.85% | +7.31% |
| 1-year return | +29.05% | +13.50% |
| 5-year return | +4.03% | +222.16% |
| P/E ratio (TTM) | 32.16 | 35.39 |
| Forward P/E | 17.94 | 31.20 |
| EPS (TTM) | $8.05 | $17.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.31B | $2.53B |
| Revenue growth (YoY) | +5.87% | +19.97% |
| Net income (latest FY) | $1.36B | $451.12M |
| Gross margin | 33.29% | — |
| Operating margin | 13.38% | 21.14% |
| Net margin | 8.34% | 17.83% |
| 52-week high | $277.40 | $677.90 |
| 52-week low | $154.50 | $373.00 |
| Distance from 52-week high | -6.68% | -11.09% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +12.35% | -1.80% |
| Average volume | 1.45M | 272.38K |
| Shares outstanding | 164.60M | 27.91M |
| Employees | 94,000 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IQVIA is about 2.5 times larger than Medpace by market value ($42.61B vs $16.82B).
- IQV has outperformed MEDP by 15.6 percentage points over the past year.
- Medpace is more profitable, keeping 17.8 cents of every revenue dollar as net income versus 8.3 cents for IQVIA.
- Medpace grew revenue faster in its latest fiscal year (+19.97% vs +5.87%).
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 94,000 employees
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
IQV vs MEDP FAQ
Which is bigger, IQVIA or Medpace?
IQVIA (IQV) is larger, with a market capitalization of $42.61B compared with $16.82B for Medpace (MEDP).
Which stock has performed better over the past year, IQV or MEDP?
IQV returned +29.05% over the past 12 months, compared with +13.50% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IQV or MEDP?
IQV has the lower trailing P/E at 32.2, versus 35.4 for MEDP. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are IQVIA and Medpace in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.